KDM6B and cancer: Among the genes studied, the chromatin modifier KDM6B stood out in that it demonstrated a consistently significant positive effect size in the thyroid (0.46, SKAT-O FDR = 2%, in ASE), our GTex-discovery tissue, and in the TCGA-matched cancer type THCA (0.98, SKAT-O FDR = 0.5%, in ASE) (Fig. 5D and Additional File 1: Fig. S24A-B).